Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform, Toxicology, vol.111, issue.1-3, pp.289-303, 1996. ,
DOI : 10.1016/0300-483X(96)03383-5
Applying Simulation Modeling to Problems in Toxicology and Risk Assessment: A Short Perspective, Toxicology and Applied Pharmacology, vol.133, issue.2, 1995. ,
DOI : 10.1006/taap.1995.1140
Risk assessment of low-level chemical exposures from consumer products under the U.S. Consumer Product Safety Commission chronic hazard guidelines, Environ Health Perspect, vol.106, pp.387-90, 1998. ,
Evaluating human variability in chemical risk assessment: hazard identification and dose-response assessment for noncancer oral toxicity of trichloroethylene, Toxicology, vol.111, issue.1-3, pp.271-87, 1996. ,
DOI : 10.1016/0300-483X(96)03382-3
Quantitative Structure???Property Relationships for Interspecies Extrapolation of the Inhalation Pharmacokinetics of Organic Chemicals, Chemical Research in Toxicology, vol.18, issue.3, pp.475-485, 2005. ,
DOI : 10.1021/tx049722k
The Integrated Use of Alternative Methods in Toxicological Risk Evaluation: ECVAM Integrated Testing Strategies Task Force Report 1, ATLA-Altern. Lab. Anim, vol.27, pp.229-237, 1999. ,
The use of Biokinetics and In Vitro Methods in Toxicological Risk Evaluation, ATLA, vol.24, pp.473-497, 1996. ,
IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans, Critical Reviews in Toxicology, vol.34, issue.10, pp.781-92, 2006. ,
DOI : 10.1080/10408440591007278
IPCS framework for analysing the relevance of a non-cancer mode of action for humans, Crit Rev Toxicol, 2007. ,
Sensitivity analysis of an environmental model; a worked application of different analysis methods. Reliability Engineering and System Safety, pp.49-69, 1997. ,
Evaluation of physiologically based pharmacokinetic models for use in risk assessment, Journal of Applied Toxicology, vol.234, issue.3, pp.218-237, 2007. ,
DOI : 10.1002/jat.1225
Key Scientific Issues in the Health Risk Assessment of Trichloroethylene, Environmental Health Perspectives, vol.114, issue.9, pp.1445-1454, 2006. ,
DOI : 10.1289/ehp.8690
Experimental Design in Systems Biology, Based on Parameter Sensitivity Analysis Using a Monte Carlo Method: A Case Study for the TNF??-Mediated NF-?? B Signal Transduction Pathway, SIMULATION, vol.79, issue.12, pp.726-739, 2003. ,
DOI : 10.1177/0037549703040943
Framework for Evaluation of Physiologically-Based Pharmacokinetic Models for Use in Safety or Risk Assessment, Risk Analysis, vol.20, issue.6, pp.1697-717, 2004. ,
DOI : 10.1007/BF00332395
A Consistent Approach for the Application of Pharmacokinetic Modeling in Cancer and Noncancer Risk Assessment, Environmental Health Perspectives, vol.110, issue.1, pp.85-93, 2002. ,
DOI : 10.1289/ehp.0211085
A physiologically based pharmacokinetic model for retinoic acid and its metabolites, Journal of the American Academy of Dermatology, vol.36, issue.3, pp.77-85, 1997. ,
DOI : 10.1016/S0190-9622(97)70063-X
Evaluation of the Uncertainty in an Oral Reference Dose for Methylmercury Due to Interindividual Variability in Pharmacokinetics, Risk Analysis, vol.44, issue.109, pp.547-58, 1999. ,
DOI : 10.1016/0300-483X(96)03383-5
Review and Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry, Critical Reviews in Toxicology, vol.5, issue.3, pp.329-89, 2002. ,
DOI : 10.1080/027868200303948
Dose, species and route extrapolation using physiologically-based pharmacokinetic modeling, Drinking Water and Health, vol.8, pp.159-184, 1987. ,
Validation of simple and complex models in physiology and medicine, Am J Physiol, vol.246, pp.259-66, 1984. ,
Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis, Environmental Health Perspectives, vol.104, issue.Suppl 6, pp.1413-1442, 1996. ,
DOI : 10.1289/ehp.961041413
A Physiological Toxicokinetic Model for Inhaled Propylene Oxide in Rat and Human with Special Emphasis on the Nose, Toxicological Sciences, vol.95, issue.1, pp.37-62, 2007. ,
DOI : 10.1093/toxsci/kfl140
An Integrated Approach to the Prediction of Systemic Toxicity using Computer-based Biokinetic Models and Biological In vitro Test Methods: Overview of a Prevalidation Study Based on the ECITTS Project, Toxicology in Vitro, vol.13, issue.4-5, pp.549-554, 1999. ,
DOI : 10.1016/S0887-2333(99)00030-2
The Utility of PBPK in the Safety Assessment of Chloroform and Carbon Tetrachloride, Regulatory Toxicology and Pharmacology, vol.32, issue.2, pp.144-55, 2000. ,
DOI : 10.1006/rtph.2000.1419
PBPK models in risk assessment???A focus on chloroprene, Chemico-Biological Interactions, vol.166, issue.1-3, 2007. ,
DOI : 10.1016/j.cbi.2007.01.016
Physiologically Based Pharmacokinetic Models in Integrated Risk Information System Assessments, Toxicokinetics and Risk Assessment, pp.301-348 ,
A mathematical model for the absorption and metabolism of formaldehyde vapour by humans, Toxicology and Applied Pharmacology, vol.206, issue.3, pp.309-329, 2005. ,
DOI : 10.1016/j.taap.2004.11.012
Physiologically based pharmacokinetic modelling of human exposure to 2-butoxyethanol, Toxicology Letters, vol.162, issue.2-3, pp.164-73, 2006. ,
DOI : 10.1016/j.toxlet.2005.09.012
Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models, J. Expos. Anal. Environ. Epidem, vol.4, pp.309-328, 1994. ,
Optimal Design for Multivariate Response Pharmacokinetic Models, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.2, pp.97-124, 2006. ,
DOI : 10.1007/s10928-006-9009-1
The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective, Science of The Total Environment, vol.288, issue.1-2, pp.3-11, 2002. ,
DOI : 10.1016/S0048-9697(01)01108-1
Propylene Oxide in Blood and Soluble Nonprotein Thiols in Nasal Mucosa and Other Tissues of Male Fischer 344/N Rats Exposed to Propylene Oxide Vapors--Relevance of Glutathione Depletion for Propylene Oxide-Induced Rat Nasal Tumors, Toxicological Sciences, vol.83, issue.1, pp.177-89, 2005. ,
DOI : 10.1093/toxsci/kfi006
Practical application of kinetic data in risk assessment???an IPCS initiative, Toxicology Letters, vol.138, issue.1-2, pp.151-60, 2003. ,
DOI : 10.1016/S0378-4274(02)00371-5
A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action, Critical Reviews in Toxicology, vol.67, issue.2, pp.591-653, 2003. ,
DOI : 10.1080/15287399409531914
Guidance for the development of chemical specific adjustment factors -integration with mode of action frameworks Informa Healthcare, 2006. ,
Guidelines for application of chemical specific adjustment factors (CSAF) in dose/concentration response assessment, Comments in Toxicology, vol.7, pp.575-590, 2001. ,
Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. Toxicol, pp.181-182, 2002. ,
Lumping of whole-body physiologically based pharmacokinetic models, Journal of Pharmacokinetics and Pharmacodynamics, vol.26, issue.1, pp.21-46, 1998. ,
DOI : 10.1023/A:1023272707390
Evaluation (not validation) of quantitative models, Environmental Health Perspectives, vol.106, issue.Suppl 6, pp.1453-60, 1998. ,
DOI : 10.1289/ehp.98106s61453
Dosimetry by means of DNA and hemoglobin adducts in propylene oxide-exposed rats, Toxicology and Applied Pharmacology, vol.191, issue.3, pp.245-54, 2003. ,
DOI : 10.1016/S0041-008X(03)00253-9
Practicing safe modeling: GLP for biologically based mechanistic models, Environmental Health Perspectives, vol.104, issue.8, 1996. ,
DOI : 10.1289/ehp.96104806
The use and abuse of models, Journal of Pharmacokinetics and Biopharmaceutics, vol.210, issue.3, pp.327-371, 1987. ,
DOI : 10.1007/BF01066325
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science, Annual Review of Pharmacology and Toxicology, vol.51, issue.1, pp.1-12, 2002. ,
DOI : 10.1146/annurev-pharmtox-010510-100540
IPCS Conceptual Framework for Evaluating a Mode of Action for Chemical Carcinogenesis, Regulatory Toxicology and Pharmacology, vol.34, issue.2, pp.146-52, 2001. ,
DOI : 10.1006/rtph.2001.1493
Update to the Health Assessment Document and Addendum for Dichloromethane (Methylene Chloride): Pharmacokinetics, Mechanism of Action, and Epidemiology, External Review Draft. EPA, vol.600, pp.8-87, 1987. ,
Risk Assessment Guidance for Superfund Human Health Evaluation Manual (Part A) EPA, pp.1-89, 1989. ,
Guidelines for Carcinogen Risk Assessment (Final) EPA, 2005. ,
Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (Final Report), 2006. ,